Cassava Sciences Inc
NASDAQ:SAVA

  • LAST PRICE
    28.5100
  • TODAY'S CHANGE (%)
    0.1200 (0.4227%)
  • Bid / Lots
    28.5200/ ---
  • Ask / Lots
    28.5500/ ---
  • Open / Previous Close
    28.2000 / 28.3900
  • Day Range
    26.8083
    29.6900
  • 52 Week Range
    8.7900
    42.2000
  • Volume
    2,615,436

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Aug 8, 2024

      Show headlines and story abstract

    • 2:37PM ET on Thursday Aug 08, 2024 by Dow Jones
      Companies Mentioned: SAVA

      Ratings actions from Benzinga: https://www.benzinga.com/quote/SAVA/analyst-ratings

      (END) Dow Jones Newswires

      August 08, 2024 14:37 ET (18:37 GMT)

    • 10:28AM ET on Thursday Aug 08, 2024 by MT Newswires
      Companies Mentioned: SAVA
      10:28 AM EDT, 08/08/2024 (MT Newswires) -- Cassava Sciences (SAVA) shares dropped nearly 18% in recent Thursday trading after the company said it expects a $40 million charge in the second half of the year to resolve the US Securities and Exchange C...

    • 8:00AM ET on Thursday Aug 08, 2024 by GlobeNewswire
      Companies Mentioned: SAVA

    • 8:00AM ET on Thursday Aug 08, 2024 by Dow Jones
      Companies Mentioned: SAVA

      This news release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, that may include but are not limited to statements regarding: the potential for advanced discussions with SEC to result in a resolution of the SEC investigation and our loss contingency estimates related thereto; our ability to extend our existing open-label extension trials, as contemplated or at all; the design, scope, conduct, continuation, completion, intended purpose, or future results of our on-going Phase 3 program of simufilam in patients with Alzheimer's disease; the timing of anticipated milestones; the assessment of interim safety data for the Phase 3 program at prior DSMB meetings; the treatment of people with Alzheimer's disease dementia; the safety or efficacy of simufilam in people with Alzheimer's disease dementia; expected cash balances and cash use in future periods; comments made by our employees regarding simufilam, drug effects, and the treatment of Alzheimer's disease; and potential benefits, if any, of our product candidates. These statements may be identified by words such as "anticipate," "believe," "could," "expect," "forecast," "intend," "may," "plan," "possible," "potential," "will," and other words and terms of similar meaning.

    • 8:00AM ET on Thursday Aug 08, 2024 by Dow Jones
      Companies Mentioned: SAVA

      This news release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, that may include but are not limited to statements regarding: the potential for advanced discussions with SEC to result in a resolution of the SEC investigation and our loss contingency estimates related thereto; our ability to extend our existing open-label extension trials, as contemplated or at all; the design, scope, conduct, continuation, completion, intended purpose, or future results of our on-going Phase 3 program of simufilam in patients with Alzheimer's disease; the timing of anticipated milestones; the assessment of interim safety data for the Phase 3 program at prior DSMB meetings; the treatment of people with Alzheimer's disease dementia; the safety or efficacy of simufilam in people with Alzheimer's disease dementia; expected cash balances and cash use in future periods; comments made by our employees regarding simufilam, drug effects, and the treatment of Alzheimer's disease; and potential benefits, if any, of our product candidates. These statements may be identified by words such as "anticipate," "believe," "could," "expect," "forecast," "intend," "may," "plan," "possible," "potential," "will," and other words and terms of similar meaning.

Peers Headlines